natgillin/translations-raw huggingface dataset:
Use of a composition comprising: one or more aldehyde-releasing biocides and/or biocides with one or more aldehyde groups in an amount such that the total amount of aldehyde-releasing biocides and/or biocides with one or more aldehyde groups in the aqueous preparation is from 250 ppm to 5000 ppm, calculated relative to the weight of water in the preparation, and 
(a) jedan ili više biocida koji oslobađaju aldehid i/ili biocidi s jednom ili više aldehidnih skupina u količini tako da je ukupna količina biocida koji oslobađaju aldehid i/ili biocida s jednom ili više aldehidnih skupina u vodenom pripravku od 250 ppm do 5000 ppm, izračunato u odnosu na težinu vode u pripravku, te
A compound according to claim 12 for use in the treatment of a disease or pathological condition susceptible to ameliorate by modulation of the adenosine A3 receptor selected from the group consisting of neurological disorders, cardiovascular diseases, respiratory diseases, renal diseases, cancer, autoimmune diseases, diseases of the gastrointestinal system and ophthalmologic diseases or conditions. 
Spoj u skladu s patentnih zahtjeva 1 do 10, naznačen time što je namijenjen upotrebi u liječenju bolesti ili patološkog stanja kojeg se može ublažiti moduliranjem adenozinskog receptora A3, kojeg se bira iz skupine koju čine Alzheimerova bolest, Huntingtonova bolest, Parkinsonova bolest, ateroskleroza, astma, rak, akutna bubrežna insuficijencija, reumatoidni artritis, Crohnova bolest, kolitis, sindrom iritabilnih crijeva, glaukom, sindrom suhih očiju i uveitis.
2 shows the microscopic analysis of crystallized PET; obtained according to the example 1 as mentioned further below. 
Slika 2 pokazuje mikroskopsku analizu kristaliziranog PET-a; dobivenog u skladu s Primjerom 1 kako je spomenuto dalje ispod.
Preferably, the further reciprocal connection means is arranged to connect to the connection means of either one of the headwear means and the further headwear means to place the further attachment means in the same orientation relative to the headset in use. An aforesaid reciprocal connection means may define an aperture through which an aforesaid headwear connection means is shaped to extend, for example. 
Slušalice prema zahtjevu 7 ili 8, naznačene time, da je recipročni spojni uređaj od dodatnog priključnog uređaja, namješten za spajanje s naglavnim spojnim uređajem na bilo kojoj od dvije školjke za uho, u svrhu postavljanja dodatnog priključnog uređaja u istu orijentaciju u odnosu na prvu i drugu školjku za uho od slušalica prilikom uporabe.
wherein the fourth stream is subjected to an evaporation step to produce a syrup; 
(i) naznačen time da se četvrta struja podvrgava koraku isparavanja da se dobije sirup;
The PET container of claim 1 or 2 wherein the density of the wall is greater than 1.375 g/cc, preferably about 1.385 g/cc. 
PET posuda iz patentnog zahtjeva 1 ili 2 gdje je gustoća zida većaod 1.375 g/cc, poželjno oko 1.385 g/cc.
A is selected from the group consisting of phenyl, napthyl and heteroaryl; 
A je izabrano iz grupe koju čine fenil, naftil i heteroaril;
The term “susceptible neoplasm” refers to an abnormal growth of tissue in mammals capable of being treated by the oral administration of the compound of formula I. As this prodrug will hydrolyze to gemcitabine, the administration of the prodrug is expected to have a broad spectrum of activity against a wide variety of tumor types, both solid and non-solid. 
Termin "osjetljiva novotvorina" odnosi se na abnormalni rast tkiva kod sisavaca kojeg se može liječiti oralnom primjenom spoja formule I. Kako se taj predlijek hidrolizira u gemcitabin, očekuje se da će primjena ovog predlijeka imati širok spektar aktivnosti protiv širokog raspona oblika tumora, 1 čvrstih 1 onih koji to nisu.
A method of signal processing to detect a change in a surface of a wall using a pulse of input ultrasonic vibrations transmitted into a proximal surface of said wall, said pulse of input ultrasonic vibrations propagating through said wall and reflecting from a distal surface of said wall to form a current pulse of output ultrasonic vibrations at said proximal surface, said method comprising the steps of: comparing said current pulse of ultrasonic vibrations with a previously detected pulse of output ultrasonic vibrations reflected from said distal surface of said wall and received at said proximal surface to detect changes in said surface of said wall. 
širi se kroz navedenu stjenku i reflektira od distalne površine navedene stjenke tako da tvori trenutni impuls izlaza ultrazvučnih vibracija na navedenoj proksimalnoj površini, te navedeni postupak sadrži korake: usporedbe navedenog trenutnog impulsa ultrazvučnih vibracija s prethodno detektiranim impulsom izlaza ultrazvučnih vibracija reflektiranim od navedene distalne površine navedene stjenke i primljenih na navedenoj proksimalnoj površini radi otkrivanja promjena u navedenoj površini navedene stjenke.
glycopyrronium bromide at a dosage in the range of 0.5-100 µg per actuation; and 
glikopironijev bromid u rasponu doze od 0.5 – 100 µg po aplikaciji, te
The receiver of section E, wherein the Layer 1 signaling data has Program Specific Information(PSI) and Service Information(SI) reprocessing information for each Physical Layer Pipe (PLP), and the PSI/SI reprocessing information indicates whether or not a PSI/SI reprocessing has been performed. 
Prijamnik iz patentnog zahtjeva 5, gdje signalni podaci Razine 1 imaju programski specifičnu informaciju (PSI) 1 servisnu informaciju (SI) ponovo obrađuju informaciju za svaku cijev fizičke razine (PLP), i ponovna obrada PSI/SI informacija ukazuje je li ili nije provedena ponovna obrada PSISI.
A composition comprising (A) compound A-1.2 and the insecticide of formula B-7.1. 
Pripravak koji je pogodan za nadzor bolesti uzrokovanih fitopatogenim organizmima uključujući (A) spoj formule I
72 g of talk were added to the resulting solution and the suspension was homogenised in an appropriate mixer unit until a substantially homogeneous suspension was obtained. 
U dobivenu otopinu doda se 72 g talka, a suspenziju homogenizira u odgovarajućoj jedinici za miješanje do postizanja uglavnom homogene suspenzije.
injecting a hydro-alcoholic solution into said bakery product, while said bakery product has a temperature of between 85° C. and 95° C. in its central part, in such a quantity as to bring the moisture content of said bakery product to a value of between 30% and 33% by weight of its total weight, 
ubrizgavanja hidroalkoholne otopine u navedeni pekarski proizvod, dok je još topao, u količini koja dovodi sadržaj vlage u spomenutom pekarskom proizvodu na vrijednost sadržanu između 30% i 33% po težini njegove ukupne težine,
Vaccine formulation comprising a peptide consisting of SEQ ID No. 115 or functional equivalents thereof. 
Formulacija cjepiva, naznačena time, da obuhvaća peptid koji se sastoji od SEQ ID NO:52.
The compound of any one of claims 1-2, wherein X is an optionally substituted phenyl group, wherein the substituents are selected from the group consisting of C1-C4 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkyloxy, C1-C4 alkoxy, CF3, carboxy, alkoxyalkyl, C1-C4 cycloalkylalkoxy, amino, alkylamino, dialkylamino, amido, alkylamido, dialkylamido, thioalkyl, halogen, cyano, alkylsulfonyl and nitro. 
Spoj prema bilo kojem od zahtjeva 1-2, naznačen time da je X opcionalno supstituirana skupina fenila, naznačen time da se ti supstituenti biraju iz skupine koju sačinjavaju Ci-Ca alkil, C3-Cg cikloalkil, Cz-Cg cikloalkiloksi, Cj-Ca alkoksi, CF, karboksi, alkoksialkil, Cy-C, cikloalkilalkoksi, amino, alkilamino, dialkilamino, amido, alkilamido, dialkilamido, tioalkil, halogen, cijano, alkilsulfonil 1 nitro.
Chemical transformation of a compound with formula III to the corresponding diazonium compound and subsequent reaction with a thiophenol of formula IV 
b) Kemijskom transformacijom spoja formule IP u odgovarajući diazonijev spoj i potom reakcijom tiofenolom formule IV liti
contacting said biological sample with a DNA primer pair comprising DNA molecules of at least 18 contiguous nucleotides of SEQ ID NO:3 or its complement, SEQ ID NO:4 or its complement, SEQ ID NO:5 or its complement, to function as DNA primers or probes diagnostic for DNA extracted from corn plant MON89034 or progeny thereof; providing a nucleic acid amplification reaction condition; 
(a) miješanje spomenutog biološkog uzorka sa parom DNA začetnica koje sadrže DNA molekule od najmanje 18 u nizu poredanih nukleotida SEQ ID NO: 3 ili njenih komplementarnih sekvenci, SEQ ID NO: 4, ili njenih komplementarnih sekvenci, SEQ ID NO: 5 ili njenih komplementarnih sekvenci, da funkcioniraju kao DNA začetnice ili dijagnostičke probe za DNA izdvojenu iz biljke kukuruza oznake MON89034 ili njenih potomaka;
and R8 are the same or different and each represent a hydrogen atom, a C1-6 alkyl group, a C3-8 cycloalkyl group, an aryl group, or a heterocyclic group (the C1-6 alkyl group, the C3-8 cycloalkyl group, the aryl group and the heterocyclic group may be substituted with 1 to 4 substituents which are the same or different and are selected from the group of substituents, Rc, to be shown below), 
R' i Rž su isti ili različiti i svaki predstavljaju vodikov atom, skupinu C,g4 alkil, skupinu C3.g cikloalkil, arilnu skupinu, ili heterocikličku skupinu, pri čemu skupina Cig alkil, skupina C3.g cikloalkil, arilna skupina i heterociklička skupina mogu biti supstituirane s 1 do 4 supstituenata koji su isti ili različiti i odabrani su iz skupine supstituenata, R", koji će biti prikazani niže,
Adhesive composition in form of a paste according to one or more of the previous claims 1-4, 6-8, 10-11, 14-15, comprising also an inert agent or inorganic filler selected among sulphates, chlorides or carbonates of sodium, magnesium, potassium, ammonium or calcium, soluble or insoluble, in an amount ranging of from 0.1 to 30% by weight, preferably of from 0.1 to 10% by weight and still more preferably equal to 5% by weight, with respect to the total weight of the adhesive composition, and a stabilizing agent selected among hydrolysed proteins, urea, hydroxyethylurea and alkyl lactate in an amount ranging of from 0.1 to 10% by weight, preferably of from 0.1 to 5% by weight and still more preferably equal to 0.6% by weight, with respect to the total weight of the adhesive composition. 
Adhezivna kompozicija u obliku paste u skladu sa jednim ili više prethodnih patentnih zahtjeva 1-4, 6-8, 10-I1i 14, pri čemu je maseni odnos adhezivni promoter/silicij dioksid u rasponu od 75:25 do 56:44, poželjno jednako Adhezivna kompozicija u obliku paste u skladu sa jednim ili više prethodnih patentnih zahtjeva 1-4, 6-8, 10-11, 14-15, koja također sadrži inertni agens ili neorganski punilac odabran između sulfata, klorida ili karbonata natrija, magnezija, kalija, amonijaka ili kalcija, topljivi ili netopljivi, u količini u rasponu od 0.1 do 30% po masi, poželjno HR P20191849 T1 od 0.1 do 10% po masi i još poželjnije jednako 5% po masi, u odnosu na ukupnu masu adhezivne kompozicije, i agens za stabilizaciju odabran između hidroliziranih proteina, uree, hidroksietiluree i alkil laktata u količini u rasponu od 0.1 do 10% po masi, poželjno od 0.1 do 5% po masi i još poželjnije jednako 0.6% po masi, u odnosu na ukupnu masu adhezivne kompozicije.
A method as claimed in claim 1, comprising urging the material such that the apex or peak of the projections are free from contact with the other tool during forming. 
Postupak prema zahtjevu 12, naznačen time da se sastoji od pritiska na materijal (17) tako da vršak ili vršci izbočina (11) nisu u kontaktu sa drugim alatom (19) tijekom oblikovanja.
The composition according to claim 1, wherein component (A) is 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide. 
Pripravak prema zahtjevu 1, naznačen time da je komponenta (A) 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid i komponenta (B) je odabrana od azoksistrobina i pikoksistrobina.
The method according to claim 1, wherein the disease or disorder is ovarian cancer. 
Spoj za uporabu prema zahtjevu 1, naznačen time, da bolest ili poremećaj je glioblastom.
A system according to any preceding claim, in which the male connection member is a giving set spike for the administration of medical fluids, and the female connection member forms an access port into a medical fluid container. 
Sustav prema bilo kojem prethodnom zahtjevu, naznačen time da je muški spojni element (300, 1200) namijenjen kao šiljak za probadanje za davanje medicinskih fluida, a ženski spojni element (10, 1010) tvori pristupni priključak u spremnik medicinskog fluida.
the assembly further comprising: 
gdje sklop dodatno ima:
in a suitable organic solvent; 
(D u prikladnom organskom otapalu;
The print medium of claim 2, wherein the base layer is a wood free paper or a wood containing paper, preferably having a basis weight from 30 to 300 g/m2. 
Tiskovna podloga prema zahtjevu 1, naznačena time da je osnovni sloj papir bez drvenog sadržaja ili papir koji sadrži drvo, poželjno ima baznu težinu od 30 do 300 g/m.
The compound of Formula XXXIV can then be deformylated to form a compound of Formula XXXV. 
Formula XVII skidanje zaštite sa spoja Formule XVII, čime se dobiva spoj Formule XVIII:
a mutated form of the wt human PSMA on the cell surface, wherein the amino acid residues at positions 140, 169, 191, 308, 334, 339, 344, 624, 626, 716, 717 and 721 are mutated to the corresponding amino acid residues of the wt rodent PSMA; and 
(ii) mutirani oblik ljudskog PSMA divljeg tipa na površini stanice, gdje su aminokiselinski ostaci na položajima 140, 169, 191, 308, 334, 339, 344, 624, 626, 716, 717 1 721 mutirani u odgovarajuće aminokiselinske ostatke PSMA glodavca divljeg tipa; i
providing an oligosaccharide comprising a first reactive group, wherein the oligosaccharide is 
(a) osiguravanje oligosaharida koji sadrži prvi reaktivnu skupinu, pri čemu je oligosaharid
wherein R1 is a bicyclic ring system which contains 9 to 11 ring members including 1 to 4 hetero atoms, in which said bicyclic ring system may be substituted by 1 to 3 groups selected from the group consisting of C1-C6alkyl, substituted C1-C6alkyl, C3-C7cycloalkyl, halo, hydroxyl, oxo, amide, carboxylic acid, —C(O)Ra, —SO2Ra, arylalkyl, —(C1-C3alkyl)aryloxy, aryl, heteroaryl and C1-C4alkoxy, in which each Ra is independently C1-C6alkyl, substituted C1-C6alkyl or unsubstituted C3-C7cycloalkyl; each R2 and R3 is independently hydrogen, C1-C6alkyl, substituted C1-C6alkyl, halo, hydroxyl, amide, carboxylic acid or C1-C4alkoxy; and m is 0-2; 
R, je biciklički sustav prstena koji sadrži 9 do 11 članova u prstenu, uključujući 1 do 4 heteroatoma,, koje se neovisno bira iz skupine koju čine N, O, te S, gdje navedeni biciklički sustav prstena može biti supstituiran s 1 do 3 skupine, koje se bira iz skupine koju čine C,-Cy4alkil, supstituirani Cy-Cgalkil, C3-C;cikloalkil, halogen, hidroksil, okso, amid, karboksilna kiselina, -C(O)R,, -SO>R,, arilalkil, (C,-Csalkil)ariloksi, aril, heteroaril i C,-C,alkoksi, gdje je svaki R, neovisno C,-Csalkil, supstituirani C;-Csalkil ili nesupstituirani C3-Crcikloalkil; svaki R> i Rs je neovisno vodik, C,-Cgalkil, supstituirani C,-Csalkil, halogen, hidroksil, amid, karboksilna kiselina ili C,-Cualkoksi; i m je 0-2; ili njegova farmaceutski prihvatljiva sol.
A product comprising (a) a PDE4 inhibitor and (b) an antagonist of M3 muscarinic receptors as defined in claim 1 or 2, as a combined preparation for simultaneous, concurrent, separate or sequential use in the treatment of a patient suffering from or susceptible to a respiratory disease which responds to M3 antagonism. 
Proizvod koji sadrži (a) B2 agonist kako je definiran u bilo kojem od patentnih zahtjeva 1 13 do 6 i (b) antagonist M3 muskarinskih receptora kako je definiran u patentnom zahtjevu 1 ili 2, naznačen time, da je to proizvod u obliku kombiniranog pripravka za istovremenu, paralelnu, odvojenu ili sekvencijalnu uporabu u liječenju bolesnika koji su oboljeli ili bi mogli oboljeti od respiratorne bolesti kako je definirana u patentnom zahtjevu 10 ili 11.
Rotation of the motor means is transmitted through shaft 1000 and mating impeller 1001 thereby transmitting a rotational force to the agitating means 108 . 
Vrtnja dijelova motora se prenosi preko osovine 1000 i spojenog propelera 1001 pri čemu se prenosi sila vrtnje na dio za miješanje 108.
iv) a first burst strength greater than a second burst strength of the paper product comprising the paper coating composition devoid of the co-processed microfibrillated cellulose and inorganic particulate material composition; and/or 
prvu čvrstoću u smjeru z (unutarnju vezu) veću od druge čvrstoće u smjeru z (unutarnje veze) papirnog proizvoda koji ne sadrži suobrađenu mješavinu mikrofibrilirane celuloze i anorganskog partikuliranog materijala; i/ili
The process according to any one of the preceding claims, characterised in that the total amount of the at least one dispersing agent added before grinding step c), or before and during step c), or before and during and/or after grinding step c), is from about 0.01 to 1.25 wt%, preferably 0.05 to 1 wt%, more preferably 0.1 to 0.7 wt%, most preferably 0.3 to 0.5 wt% based on the dry weight of the mineral material. 
Postupak prema zahtjevu 4, naznačen time da ukupna količina najmanje jednog disperzijskog sredstva koja je dodana prije koraka mljevenja c), ili prije 1 tijekom koraka c), ili prije i tijekom i/ili nakon koraka mljevenja c), je od oko 0.01 do 1.25 % tež., poželjno 0.05 do 1 % tež., poželjnije 0.1 do 0.7 % tež., najpoželjnije 0.3 do 0.5 % tež. bazirano na težini suhog mineralnog materijala,
The presence of detergent will generally be maintained in order to ensure IL-2 solubility. 
Prisutnost deterdženta će se općenito održavati da bi se osigurala topivost IL-2.
The PET container of claim 3 wherein the wall of the container has a moisture content of from about 1850 ppm to about 1930 ppm when exposed to ambient conditions for 4 days. 
PET posuda iz patentnog zahtjeva 1 gdje zid posude ima sadržaj vlage od oko 1780 ppm do oko 1980 ppm kada je izložen uvjetima vrućeg punjenja na oko 96?
Furthermore, certain vitamins and minerals can be added to the basic formulation, consisting of a specific combination of the ingredients described above. 
Nadalje, osnovnoj se formulaciji mogu dodati određeni vitamini i minerali, da se postigne specifična kombinacija gore opisanih sastojaka.
The conjugate of Claim 3, wherein the heterologous moiety is a peptide and the conjugate is a fusion peptide or a chimeric peptide, or a pharmaceutically acceptable salt thereof. 
Konjugat u skladu s patentnim zahtjevom 3, naznačen time što je heterologni ostatak peptid, a konjugat je fuzijski peptid ili kimerni peptid, ili njegova farmaceutski prihvatljiva sol.
X is selected from the group consisting of methyl, ethyl, propyl, butyl, benzyl, substituted benzyl, naphthylmethyl, substituted naphthylmethyl, and other substituted and unsubstituted C1 to C10 aliphatic or aromatic groups; the various Xs may be the same or different. 
X je odabran iz grupe koja se sastoji od metila, etila, propila, butila, benzila, supstituiranog benzila, naftilmetila, supstituiranog naftilmetila i drugih supstituiranih i nesupstituiranih C1 do C10 alifatskih ili aromatskih grupa; 2. Tvar iz patentnog zahtjeva 1 ima strukturu
Water (100 ml) was added and the reaction mixture was heated to 70° C. The product was precipitated by slowly adding more water (200 ml). 
Dodana je voda (100 ml), a reakcijska smjesa je grijana do 70*C. Produkt je precipitiran polaganim dodavanjem vode (200 ml).
represents a hydrogen atom or a C1-C6 alkyl group, and represents a phenyl group, a thienyl group, a thiazolyl group, a pyridyl group, a naphthyl group, an indanyl group, a dihydrobenzofuranyl group, a benzodioxolyl group, a benzothiadiazolyl group, a benzothienyl group or a quinolinyl group, each of which may be substituted with 1 to 5 substituents selected from the group C [wherein the group C consists of a C1-C6 alkyl group, a halogen atom, a trifluoromethyl group, a C1-C6 alkoxy group, a trifluoromethoxy group, a nitro group, a cyano group, and a C2-C7 alkanoyl group], or a C2-C8 alkenyl group which may be substituted with a phenyl group(s). 
HR P20120363 T1 morfolino skupinu, piperazino skupinu koja može biti supstituirana sa C,-C4 alkil skupinom(ama), Cj-Cg alkanoilamino skupinu, te Ci-Cg alkilsulfonilamino skupinu], R* predstavlja atom vodika ili C,-Cg alkilnu skupinu, i R* predstavlja fenilnu skupinu, tienil skupinu, tiazolil skupinu, piridil skupinu, naftil skupinu, indanil skupinu, dihidrobenzofuranil skupinu, benzodioksolil skupinu, benzotiadiazolil skupinu, benzotienil skupinu ili kinolinil skupinu, od kojih svaka može biti supstituirana sa 1 do 5 supstituenta odabranih iz skupine € [pri čemu skupina C sadrži C,-C4 alkilnu skupinu, atom halogena, trifluorometilnu skupinu, C;,-C4 alkoksi skupinu, trifluorometoksi skupinu, nitro skupinu, cijano skupinu, te C2-C; alkanoil skupinu], ili C,-Cg alkenil skupinu koja može biti supstituirana sa fenil skupinom(ama)).
For preparation of the wood preservative solution according to the present invention a carboxylic acid is selected from the group consisting of hexanoic acid, octanoic acid and decanoic acid. 
Za dobivanje otopine drvnog konzervansa prema ovom izumu, karboksilna kiselina je odabrana iz skupine koju sačinjavaju heksanoična kiselina, oktanoična kiselina i dekanoična kiselina.
After stirring for 30 minutes the resulting suspension is filtered and dried in vacuo at 110°C to yield the titled product as a yellow solid. (MH+ 326) 
Nakon miješanja 30 minuta dobivenu suspenziju se profiltrira i osuši u vakuumu pri 110"C, čime se dobije naslovni proizvod kao žuta krutina.
A composition according to claim 1 comprising; 20-40% preferably 20-35% by weight on a dry weight basis of a DPP-IV inhibitor in free form or in acid addition salt form; 
od 22 do 28 masenih postotaka na bazi suhe mase inhibitora DPP-IV koji je (S)-1-[(3-hidroksi-1-adamantil)amino]acetil-2-cijanopirolidin u slobodnom obliku ili u obliku kiselinske adicijske soli;
The distributed computing system of any one of the claims 8 to 9, wherein the encoder (11) is adapted to use a k x m-Beta random number matrix to encode the first data-set, wherein the first communication device comprises means for encapsulating each of the k encoded elements along with the entries of the respective row of the Beta random number matrix into a separate packet, and wherein the decoder (24) is adapted to compute the inverse of the received Beta random number matrix. 
Distribuirani računalni sustav u skladu s bilo kojim od patentnih zahtjeva 8 do 9, naznačen time što koder (11) je podešen za upotrebu k x m-Beta matrice slučajnih brojeva kako bi se kodirao prvi podatkovni niz, gdje prvi komunikacijski uređaj sadrži inkapsulator za svaki od k kodiranih elemenata uz članove odgovarajućeg reda Beta matrice slučajnih brojeva u odvojeni paket, te gdje je dekoder (24) podešen za izračunavanje inverzije primljene Beta matrice slučajnih brojeva.
represents a group selected from 
predstavlja grupu odabranu iz
The method according to claim 20, wherein the plant or the seed from which the plant develops is selected from wheat, barley, rye, cucumber, cotton, soybeans, common beans, tomatoes, potatoes, peanuts or coffee. 
Metoda u skladu sa patentnim zahtjevom 20, naznačena time da je biljka ili sjeme iz koje se biljka razvija, odabrana između žita, ječam, raž, krastavac, pamuk, soja, običan grah, rajčica, krumpir, kikiriki ili kava.